We rounded off an insightful first day of the conference with additional engaging presentations, including:

• Pharvaris (#PHVS) | Moderated by Pete Stavropoulos, Ph.D. – Morgan Conn (CBO) discussed the company’s oral small-molecule bradykinin B2 receptor antagonist PHVS416, and its potential utility in hereditary angioedema.

• Lyra Therapeutics (#LYRA) | Moderated by Louise Chen – Maria Palasis, Ph.D. (President & CEO) discussed chronic rhinosinusitis (CRS) market and LYRA’s pipeline, which includes LYR-210 in surgically naïve patients and LYR-220 for post-surgical patients. Maria reviewed the latest Phase 2 BEACON data and discussed LYRA’s potential next steps. Louise and Maria also talked about the expectations heading into LYRA’s topline results from its Phase 3 ENLIGHTEN I study, which the company expects in 1H24.

• Taysha Gene Therapies (#TSHA) | Moderated by Kristen Kluska – Sean Nolan (CEO) and Dr. Sukumar Nagendran (President and Head of R&D) walked through the recent data from Taysha Gene Therapies in Rett Syndrome and provided latest thoughts on gene therapies for rare diseases.

• Asensus Surgical (#ASXC) | Moderated by Ross Osborn, CFA – Shameze Rampertab (CFO) discussed the Senhance Robotic System’s recent pediatric indication and highlighted the company’s recent collaboration with NVIDIA.

#Cantor #CantorFitzgerald #CantorHealthcare #CantorGlobalHealthcare2023